title: Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
authors.affiliation: Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, USA.
authors.forename: S Z
authors.initials: SZ
authors.lastname: Usmani
authors.affiliation: Cancer Research and Biostatistics, Seattle, WA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Sexton
authors.affiliation: Mayo Clinic, Jacksonville, FL, USA.
authors.forename: S
authors.initials: S
authors.lastname: Ailawadhi
authors.affiliation: MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Shah
authors.affiliation: Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: J
authors.initials: J
authors.lastname: Valent
authors.affiliation: City of Hope, Los Angeles, CA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Rosenzweig
authors.affiliation: University of Kansas Cancer Center, Westwood, KS, USA.
authors.forename: B
authors.initials: B
authors.lastname: Lipe
authors.affiliation: Karmanos Cancer Institute, Detroit, MI, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Zonder
authors.affiliation: SWOG Operations, San Antonio, TX, USA.
authors.forename: S
authors.initials: S
authors.lastname: Fredette
authors.affiliation: Cedar-Sinai Medical Center, Los Angeles, CA, USA.
authors.forename: B
authors.initials: B
authors.lastname: Durie
authors.affiliation: Cancer Research and Biostatistics, Seattle, WA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Hoering
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: B
authors.initials: B
authors.lastname: Bartlett
authors.affiliation: MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: R Z
authors.initials: RZ
authors.lastname: Orlowski
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage; D017321:Clinical Trials, Phase I as Topic; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D060828:Induction Chemotherapy; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C546027:elotuzumab; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide